Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of IBI311 in active or inactive thyroid eye disease
CTR20243131Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sycume in Graves Orbitopathy (GO), sponsored by InnoCare Pharma. Started Aug 2024; status: completed.
02
Drugs
sycume
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20243131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243131.